UniQure N.V. Announces Appointment of Kylie O?Keefe as Chief Customer and Strategy Officer, Effective June 6, 2025

Published: 2025-06-11 09:20:45 ET QURE

Published on 06/11/2025 at 09:20

uniQure N.V. announced the appointment of Kylie O?Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O?Keefe will lead the development and execution of uniQure?s global commercialization strategy for AMT-130, the Company?s investigational gene therapy for the treatment of Huntington?s disease. Her responsibilities include all commercial functions and medical affairs.

Ms. O?Keefe was most recently Chief Commercial Officer at PTC Therapeutics. Ms. O?Keefe is an accomplished business leader with broad biopharmaceutical experience and a proven track record in rare diseases and gene therapy. Most recently, she served as Chief Commercial Officer at PTC Therapeutics, where she led global commercial strategy, operations and portfolio management for multiple rare neurology and metabolic commercial products across more than 50 countries.

During her tenure, Ms. O?Keefe led several strategically significant commercial launches and supported corporate strategy and pipeline development for both small molecules and gene therapies including Upstaza? (AADC deficiency). She also directed the development and execution of reimbursement strategies, including payer engagement and health economic assessments, and led business development and investor relations.

Earlier in her career, Ms. O?Keefe held key roles at LEO Pharma where she launched a portfolio of pharmaceutical products in more than 30 countries. Ms. O?Keefe holds a Bachelor?s degree in Biotechnology Innovation from Queensland University of Technology in Brisbane, Australia and a Graduate diploma in Managing Medical Product Innovation from Copenhagen Business School in Frederiksberg, Denmark.